Fibroblast subtypes define a metastatic matrisome in breast cancer

JCI Insight. 2020 Feb 27;5(4):e130751. doi: 10.1172/jci.insight.130751.

Abstract

Small primary breast cancers can show surprisingly high potential for metastasis. Clinical decision-making for tumor aggressiveness, including molecular profiling, relies primarily on analysis of the cancer cells. Here we show that this analysis is insufficient - that the stromal microenvironment of the primary tumor plays a key role in tumor cell dissemination and implantation at distant sites. We previously described 2 cancer-associated fibroblasts (CAFs) that either express (CD146+) or lack (CD146-) CD146 (official symbol MCAM, alias MUC18). We now find that when mixed with human breast cancer cells, each fibroblast subtype determines the fate of cancer cells: CD146- fibroblasts promoted increased metastasis compared with CD146+ fibroblasts. Potentially novel quantitative and qualitative proteomic analyses showed that CD146+ CAFs produced an environment rich in basement membrane proteins, while CD146- CAFs exhibited increases in fibronectin 1, lysyl oxidase, and tenascin C, all overexpressed in aggressive disease. We also show clinically that CD146- CAFs predicted for likelihood of lymph node involvement even in small primary tumors (<5 cm). Clearly small tumors enriched for CD146- CAFs require aggressive treatments.

Keywords: Breast cancer; Oncology.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Breast Neoplasms / pathology*
  • CD146 Antigen / metabolism
  • ErbB Receptors / metabolism
  • Female
  • Fibroblasts / metabolism
  • Humans
  • MCF-7 Cells
  • Neoplasm Invasiveness
  • Neoplasm Metastasis*
  • Tumor Microenvironment

Substances

  • CD146 Antigen
  • MCAM protein, human
  • EGFR protein, human
  • ErbB Receptors